[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100501390":3},{"organization":4,"outcomesModule":7,"designInfo":48,"detailedDescription":54,"studyPopulation":47,"armGroups":55,"interventions":62,"overallOfficials":47,"centralContacts":67,"locations":74,"responsibleParty":208,"collaborators":47,"id":210,"slug":47,"hasResults":211,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":47,"eligibilityCriteria":215,"healthyVolunteers":211,"sex":216,"minAge":217,"maxAge":47,"enrollmentInfo":218,"targetDuration":47,"studyType":221,"phases":222,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":77,"whyStopped":47,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":240},{"fullName":5,"class":6},"BioAtla, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":18,"otherOutcomes":47},[9,13,15],{"measure":10,"description":11,"timeFrame":12},"Part 1: Assess dose limiting toxicity as defined in the protocol","Phase 1 Part 1: Safety Profile of BA3182","Up to 24 months",{"measure":14,"description":11,"timeFrame":12},"Part 1: Assess maximum tolerated dose as defined in the protocol",{"measure":16,"description":17,"timeFrame":12},"Part 2: Confirmed overall response rate (ORR) per RECIST v1.1","Phase 1 Part 2: Antitumor activity of BA3182",[19,22,25,27,29,31,33,35,37,40,42,45],{"measure":20,"description":21,"timeFrame":12},"Confirmed overall response rate (ORR) per RECIST v1.1","Phase 1 Part 1: Antitumor activity of BA3182",{"measure":23,"description":24,"timeFrame":12},"Confirmed best overall response best overall response (BOR)","Phase 1: Antitumor activity of BA3182",{"measure":26,"description":24,"timeFrame":12},"Confirmed duration of response (DOR)",{"measure":28,"description":24,"timeFrame":12},"Confirmed progression-free survival (PFS)",{"measure":30,"description":24,"timeFrame":12},"Confirmed disease control rate (DCR)",{"measure":32,"description":24,"timeFrame":12},"Confirmed time to response (TTR)",{"measure":34,"description":24,"timeFrame":12},"Confirmed overall survival (OS)",{"measure":36,"description":24,"timeFrame":12},"Confirmed percent change from baseline in target lesion sum of diameters.",{"measure":38,"description":39,"timeFrame":12},"Area under the plasma concentration versus time curve (AUC)","Phase 1: Pharmacokinetics of BA3182",{"measure":41,"description":39,"timeFrame":12},"Peak Plasma Concentration (Cmax) Phase 1: Pharmacokinetics",{"measure":43,"description":44,"timeFrame":12},"Incidence of anti-drug antibody (ADAs) to BA3182 Phase 1: Pharmacokinetics Phase 1: Immunogenicity","Phase 1: Immunogenicity of BA3182",{"measure":46,"description":44,"timeFrame":12},"Incidence of neutralizing antibodies (nAbs) to BA3182.",null,{"allocation":49,"interventionModel":50,"interventionModelDescription":47,"primaryPurpose":51,"observationalModel":47,"timePerspective":47,"maskingInfo":52},"NA","SINGLE_GROUP","TREATMENT",{"masking":53,"maskingDescription":47,"whoMasked":47},"NONE","This is a multi-center, open-label, Phase 1 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3182 in patients with advanced adenocarcinoma.",[56],{"label":57,"type":58,"description":59,"interventionNames":60},"BA3182","EXPERIMENTAL","All Patients will receive BA3182",[61],"Drug: BA3182",[63],{"type":64,"name":57,"description":65,"armGroupLabels":66,"otherNames":47},"DRUG","Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM",[57],[68],{"name":69,"role":70,"phone":71,"phoneExt":72,"email":73},"BioAtla Medical Affairs","CONTACT","858-558-0708","3333","medicalaffairs@bioatla.com",[75,94,108,123,138,149,164,179,193],{"facility":76,"status":77,"city":78,"state":79,"zip":80,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":88,"contacts":89},"UC Irvine","RECRUITING","Irvine","California","92697","United States","US",{"type":84,"coordinates":85},"Point",[86,87],-117.82311,33.66946,{"lat":87,"lon":86},[90],{"name":91,"role":70,"phone":92,"phoneExt":47,"email":93},"Chao Family Comprehensive Cancer Center","877-827-8839","ucstudy@hs.uci.edu",{"facility":95,"status":77,"city":96,"state":79,"zip":97,"country":81,"countryCode":82,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"USC Norris Comprehensive Cancer Center","Los Angeles","90033",{"type":84,"coordinates":99},[100,101],-118.24368,34.05223,{"lat":101,"lon":100},[104],{"name":105,"role":70,"phone":106,"phoneExt":47,"email":107},"Lorraine Martinez Seng","323-865-3000","Lorraine.Martinez@med.usc.edu",{"facility":109,"status":77,"city":110,"state":111,"zip":112,"country":81,"countryCode":82,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Yale Cancer Center","New Haven","Connecticut","06511",{"type":84,"coordinates":114},[115,116],-72.92816,41.30815,{"lat":116,"lon":115},[119],{"name":120,"role":70,"phone":121,"phoneExt":47,"email":122},"Ingrid Palma","203-833-1034","ingrid.palma@yale.edu",{"facility":124,"status":77,"city":125,"state":126,"zip":127,"country":81,"countryCode":82,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Northwestern University","Chicago","Illinois","60611",{"type":84,"coordinates":129},[130,131],-87.65005,41.85003,{"lat":131,"lon":130},[134],{"name":135,"role":70,"phone":136,"phoneExt":47,"email":137},"Clinical Research Office","312-695-1301","cancer@northwestern.edu",{"facility":139,"status":77,"city":125,"state":126,"zip":140,"country":81,"countryCode":82,"cosmosGeoPoint":141,"geoPoint":143,"contacts":144},"University of Illinois","60612",{"type":84,"coordinates":142},[130,131],{"lat":131,"lon":130},[145],{"name":146,"role":70,"phone":147,"phoneExt":47,"email":148},"Omer Qazi","312-413-1069","omerqazi@uic.edu",{"facility":150,"status":77,"city":151,"state":152,"zip":153,"country":81,"countryCode":82,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"Karmanos Cancer Institute","Detroit","Michigan","48201",{"type":84,"coordinates":155},[156,157],-83.04575,42.33143,{"lat":157,"lon":156},[160],{"name":161,"role":70,"phone":162,"phoneExt":47,"email":163},"Clarice Zuccaro","313-576-9375","zuccaroc@karmanos.org",{"facility":165,"status":77,"city":166,"state":167,"zip":168,"country":81,"countryCode":82,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"The Christ Hospital Cancer Center","Cincinnati","Ohio","45219",{"type":84,"coordinates":170},[171,172],-84.51439,39.12711,{"lat":172,"lon":171},[175],{"name":176,"role":70,"phone":177,"phoneExt":47,"email":178},"Abby Reed","513-585-0844","abby.reed@thechristhospital.com",{"facility":180,"status":77,"city":181,"state":167,"zip":182,"country":81,"countryCode":82,"cosmosGeoPoint":183,"geoPoint":187,"contacts":188},"University Hospitals Cleveland Medical Center","Cleveland","44106",{"type":84,"coordinates":184},[185,186],-81.69541,41.4995,{"lat":186,"lon":185},[189],{"name":190,"role":70,"phone":191,"phoneExt":47,"email":192},"Principal Investigator","216-844-3951","Madison.Conces@UHHospitals.org",{"facility":194,"status":77,"city":195,"state":196,"zip":197,"country":81,"countryCode":82,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"Fred Hutch Cancer Center","Seattle","Washington","98109",{"type":84,"coordinates":199},[200,201],-122.33207,47.60621,{"lat":201,"lon":200},[204],{"name":205,"role":70,"phone":206,"phoneExt":47,"email":207},"Phase 1 Clinical Trials","206-606-7551","phase1clinicaltrial@fredhutch.org",{"type":209,"investigatorFullName":47,"investigatorTitle":47,"investigatorAffiliation":47,"oldNameTitle":47,"oldOrganization":47},"SPONSOR","100501390",false,"NCT05808634","Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.","An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)\u002FCD3 Antibody, in Patients With Advanced Adenocarcinoma","Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma\n* Age ≥ 18 years\n* Adequate renal function\n* Adequate liver function\n* Adequate hematological function\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion Criteria:\n\n* Patients must not have clinically significant cardiac disease.\n* Patients must not have known non-controlled CNS metastasis.\n* Patients must not have active autoimmune disease or a documented history of autoimmune disease.\n* Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.\n* Patients must not incomplete recovery from the effects of major surgery or significant traumatic injury before the first dose of study treatment.\n* Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and\u002For hepatitis C.\n* Patients must not be women who are pregnant or breast feeding.","ALL","18 Years",{"count":219,"type":220},168,"ESTIMATED","INTERVENTIONAL",[223],"PHASE1","The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma",[226],"Advanced Adenocarcinoma",[228,229,230],"Advanced","Metastatic","Cancer","2025-09-22",{"date":233,"type":234},"2025-09-25","ACTUAL",{"date":236,"type":234},"2023-07-14",{"date":238,"type":220},"2028-09-15",{"name":5,"class":6},9]